π Lilly boosts outlook after Q2 2026 earnings
Eli Lilly and Company announced its financial results for the second quarter of 2026. The company reported strong performance from its ongoing drug development and sales pipeline. Key metrics showed significant growth across various segments during this period. Lilly also opted to raise its financial guidance for the entire fiscal year 2026. This positive momentum suggests sustained expansion and pipeline strength ahead.